Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1984 Oct;18(4):632–637. doi: 10.1111/j.1365-2125.1984.tb02518.x

Study of the bioavailability of pindolol in malabsorption syndromes.

D Evard, J P Aubry, Y Le Quintrec, G Cheymol, A Cheymol
PMCID: PMC1463627  PMID: 6487506

Abstract

Pindolol kinetics and bioavailability were studied after a single dose (oral 5 mg; intravenous 3 mg) in nine patients with malabsorption (two with villous atrophies, seven with short bowel syndromes) and in six healthy volunteers. After oral administration no significant differences were observed in bioavailability (59.4 +/- 6.2% in patients vs 79.5 +/- 8.6% in controls) and for most plasma and urinary pharmacokinetic parameters between the experimental and control groups as a whole. However, detailed analysis revealed decreased absorption for pindolol in two out of nine patients. After i.v. administration, apparent distribution volume was smaller (V: 2.10 +/- 0.25 l kg-1 vs 3.05 +/- 0.31 l kg-1) and global elimination constant was larger (ke: 1.43 +/- 0.46 h-1 vs 0.56 +/- 0.10 h-1), in patients with malabsorption than in controls (P less than 0.05). The smaller weight of patients and pharmacokinetic modifications due to the pathology could account for this.

Full text

PDF
632

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andreasen P. B., Danö P., Kirk H., Greisen G. Drug absorption and hepatic drug metabolism in patients with different types of intestinal shunt operation for obesity. A study with phenazone. Scand J Gastroenterol. 1977;12(5):531–535. doi: 10.3109/00365527709181330. [DOI] [PubMed] [Google Scholar]
  2. Backman L., Beerman B., Groschinsky-Grind M., Hallberg D. Malabsorption of hydrochlorothiazide following intestinal shunt surgery. Clin Pharmacokinet. 1979 Jan-Feb;4(1):63–68. doi: 10.2165/00003088-197904010-00006. [DOI] [PubMed] [Google Scholar]
  3. Gerson C. D., Lowe E. H., Lindenbaum J. Bioavailability of digoxin tablets in patients with gastrointestinal dysfunction. Am J Med. 1980 Jul;69(1):43–49. doi: 10.1016/0002-9343(80)90498-2. [DOI] [PubMed] [Google Scholar]
  4. Gugler R., Herold W., Dengler H. J. Pharmacokinetics of pindolol in man. Eur J Clin Pharmacol. 1974;7(1):17–24. doi: 10.1007/BF00614385. [DOI] [PubMed] [Google Scholar]
  5. Holt S., Heading R. C., Clements J. A., Tothill P., Prescott L. F. Acetaminophen absorption and metabolism in celiac disease and Crohn's disease. Clin Pharmacol Ther. 1981 Aug;30(2):232–238. doi: 10.1038/clpt.1981.153. [DOI] [PubMed] [Google Scholar]
  6. Kennedy M. C., Wade D. N. Phenytoin absorption in patients with ileojejunal bypass. Br J Clin Pharmacol. 1979 May;7(5):515–518. doi: 10.1111/j.1365-2125.1979.tb00996.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Lavene D., Weiss Y. A., Safar M. E., Loria Y., Agorus N., Georges D., Milliez P. L. Pharmacokinetics and hepatic extraction ratio of pindolol in hypertensive patients with normal and impaired renal function. J Clin Pharmacol. 1977 Aug-Sep;17(8-9):501–508. doi: 10.1002/j.1552-4604.1977.tb05643.x. [DOI] [PubMed] [Google Scholar]
  8. Lemaire M., Tillement J. P. The binding characteristics of some adrenergic beta-receptor antagonists to human serum proteins. Biochem Pharmacol. 1982 Feb 1;31(3):359–365. doi: 10.1016/0006-2952(82)90183-6. [DOI] [PubMed] [Google Scholar]
  9. Marcus F. I., Quinn E. J., Horton H., Jacobs S., Pippin S., Stafford M., Zukoski C. The effect of jejunoileal bypass on the pharmacokinetics of digoxin in man. Circulation. 1977 Mar;55(3):537–541. doi: 10.1161/01.cir.55.3.537. [DOI] [PubMed] [Google Scholar]
  10. Meier J., Nüesch E. Pindolol, a beta-adrenoceptor blocking agent with a negligible first-pass effect. Br J Clin Pharmacol. 1977 Jun;4(3):371–372. doi: 10.1111/j.1365-2125.1977.tb00726.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Pacha W. L. A method for the fluorimetric determination of 4-(2-hydroxy-3-isopropylaminopropoxy)-indole (LB46), a beta-blocking agent, in plasma and urine. Experientia. 1969 Aug 15;25(8):802–803. doi: 10.1007/BF01897885. [DOI] [PubMed] [Google Scholar]
  12. Parsons R. L. Drug absorption in gastrointestinal disease with particular reference to malabsorption syndromes. Clin Pharmacokinet. 1977 Jan-Feb;2(1):45–60. doi: 10.2165/00003088-197702010-00004. [DOI] [PubMed] [Google Scholar]
  13. Parsons R. L., Hossack G., Paddock G. The absorption of antibiotics in adult patients with coeliac disease. J Antimicrob Chemother. 1975 Mar;1(1):39–50. doi: 10.1093/jac/1.1.39. [DOI] [PubMed] [Google Scholar]
  14. Parsons R. L., Kaye C. M., Raymond K., Trounce J. R., Turner P. Absorption of propranolol and practolol in Coeliac disease. Gut. 1976 Feb;17(2):139–143. doi: 10.1136/gut.17.2.139. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Parsons R. L., Paddock G. M. Absorption of two antibacterial drugs, cephalexin and co-trimoxazole, in malabsorption syndromes. J Antimicrob Chemother. 1975;1(3 Suppl):59–67. doi: 10.1093/jac/1.suppl_3.59. [DOI] [PubMed] [Google Scholar]
  16. Schneider R. E., Babb J., Bishop H., Mitchard M., Hoare A. M. Plasma levels of propranolol in treated patients with coeliac disease and patients with Crohn's disease. Br Med J. 1976 Oct 2;2(6039):794–795. doi: 10.1136/bmj.2.6039.794. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES